These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31756037)

  • 1. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban.
    Jourdi G; Siguret V; Martin AC; Golmard JL; Godier A; Samama CM; Gaussem P; Gouin-Thibault I; Le Bonniec B
    Thromb Haemost; 2015 Jul; 114(1):78-86. PubMed ID: 25761505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
    Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
    Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months.
    Foulon-Pinto G; Jourdi G; Perrin J; Abdoul J; Paris G; Gouin-Thibault I; Curis E; Lecompte T; Siguret V
    Int J Lab Hematol; 2021 Aug; 43(4):821-830. PubMed ID: 33369212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of NOACs on Thrombin Generation Assay].
    Kawasugi K
    Rinsho Byori; 2014 Oct; 62(10):965-9. PubMed ID: 27526542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors.
    Schreuder M; Jourdi G; Veizaj D; Poole DA; Cheung KL; Poenou G; Verhoef D; Thomassen S; Janssen LFH; Stepanian A; Hackeng TM; Gaussem P; Reitsma PH; Geerke DP; Siguret V; Bos MHA
    J Thromb Haemost; 2024 Aug; 22(8):2211-2226. PubMed ID: 38729577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis.
    Taune VS; Zabczyk M; He S; Ågren A; Blombäck M; Wallén H; Skeppholm M
    Scand J Clin Lab Invest; 2024 Jul; 84(4):257-267. PubMed ID: 38953609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
    Wong PC; Crain EJ; Watson CA; Xin B
    J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
    Perzborn E; Heitmeier S; Buetehorn U; Laux V
    J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation.
    Kremers RM; Wagenvoord RJ; Hemker HC
    Thromb Haemost; 2016 Apr; 115(4):869-70. PubMed ID: 26467386
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.